title: Optimizing tolerability of TKI therapy in CML.
authors.affiliation: UNIVERSITÄTSKLINIKUM JENA.
authors.forename: Andreas
authors.initials: A
authors.lastname: Hochhaus
mesh_terms: D000814:Aniline Compounds / Q000009:adverse effects* / Q000627:therapeutic use*; D001549:Benzamides / Q000627:therapeutic use*; D064420:Drug-Related Side Effects and Adverse Reactions / Q000628:therapy*; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D008297:Male; D009570:Nitriles / Q000009:adverse effects* / Q000627:therapeutic use*; D010879:Piperazines / Q000627:therapeutic use*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D011804:Quinolines / Q000009:adverse effects* / Q000627:therapeutic use*
chemical_list: D000814:Aniline Compounds; D001549:Benzamides; D009570:Nitriles; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D011804:Quinolines; C471992:bosutinib; D000068877:Imatinib Mesylate